Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(625)
•••
Post by KayakerBCon Jun 28, 2017 2:46pm
208 Views
Post# 26415262

Just for a laugh...

Just for a laugh...Here's the kind of pumper post (04-2016) we can expect from DigiTroll once he's long BTI:

Evaluations are already underway and it takes 6-9 months. Some programs were in planning and some were already underway as of the December CEO comment. Stunning commercial opportunities were also mentioned in the December CEO letter. They are working with over 20 companies now. Then it can go into a licensing deal.

They also expect to move to human trials for the Herceptin product by the end of the year or early 2017.

https://business.financialpost.com/midas-letter/podcast-bioasis-technologies-inc-ceo-rob-hutchison-on-how-his-company-is-breaching-the-blood-brain-barrier-bti

A move into Phase I human testing and potential multiple licensing deals, including potential stunning commercial opportunities, should be enough for a material move higher in the stock.

(my bolding)
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities